Lamotrigine serum concentration in children with epilepsy

Eli Heyman, Revital Lavie, Eli Lahat, Rony Braunstein, Adina Bar-Haim, Matitiahu Berkovitch, Revital Gandelman-Marton*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The correlation between lamotrigine serum concentration, efficacy, and toxicity in children is controversial. The database of the Clinical Pharmacology Laboratory at Assaf Harofeh Medical Center was retrospectively searched to identify lamotrigine serum concentrations in children aged 2-19 years with refractory epilepsy who received lamotrigine as monotherapy or polytherapy from 2007-2010. Data collected included age at epilepsy onset, additional antiepileptic drugs, lamotrigine dose, monthly seizure frequency before and after lamotrigine treatment, and side effects. Sixty blood samples were collected from 42 children aged 10.1 ± 4.9 years (range, 2-20 years). Seizure types included complex partial (n = 28), simple partial (n = 7), absence (n = 2), and generalized tonic-clonic (n = 23). Decreased seizure frequency was observed in 38 (63.3%) patients. No correlation with lamotrigine serum concentration was evident, but seizure frequency was significantly influenced by age and lamotrigine dose. Side effects were reported in 21 (35%) patients. Only diplopia was significantly correlated with lamotrigine serum concentration. Lamotrigine was more effective at lower doses and in older children. Lamotrigine serum concentration correlated significantly with diplopia, but not with other side effects or with clinical efficacy. Overall, lamotrigine is effective and safe in children with refractory epilepsy.

Original languageEnglish
Pages (from-to)427-430
Number of pages4
JournalPediatric Neurology
Volume47
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Dive into the research topics of 'Lamotrigine serum concentration in children with epilepsy'. Together they form a unique fingerprint.

Cite this